Fig. 2.

Anti-CCR7 mAb mediates strong CDC of CLL cells sparing T cells in 17p- and/or fludarabine-refractory CLL. PBMC from the patients were incubated with anti-CCR7, anti-CD52 (alemtuzumab, Alem) or an isotype control (IC) at the indicated concentrations and then exposed to rabbit complement for 1.5 h. Cell lysis was determined in the different populations by staining CD19, CD3 and CD5 and analyzing 7-AAD (7-aminoactinomycin-D) incorporation by FCM. In all cases, the percentage of specific lysis was calculated according to the formula shown in “Materials and methods”. a, b CLL and T cells from patients with 17p- and fludarabine-refractory (FR) CLL (n = 5). C, d CLL and T cells from patients with 17p- and fludarabine-naïve CLL (n = 6). e and f CLL and T cells from patients without 17p deletion and FR-CLL (n = 4). All statistical analyses are referred to CCR7. Each dot, square or triangle represents mean ± standard mean error. *p < 0.05; **p < 0.01; ***p < 0.001